FDA approves 3+ new blockbuster drugs by December 31 2026

The agency streamlines clinical trials under interim leadership, approving at least 3 drugs with peak annual sales exceeding $1B by year-end 2026. Regulatory predictability improves despite Makary's departure.

Implied probability (Yes)

62%